"It is very rewarding to be at the forefront of cancer immunotherapy and to apply innovative and cutting-edge technologies to gain a glimpse into each patient’s unique immune response against our immunotherapy drugs."
My passion for human immunology and my vision to apply innovative technologies to study the immune response of patients undergoing cancer immunotherapy brought me to Oncology Biomarker Development (OBD) at Genentech in 2018. At Genentech, I have served as the Biomarker Sub-team Lead (BMSTL) for several of our early stage CIT programs.
Cytometry B Clin Cytom. 2021 Jan;100(1):10-18.
J Virol. 2020 Dec 22;95(2):e01331-20.
Nat Commun. 2019 Sep 25;10(1):4344.
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8939-E8947.
My group focuses on: